Bookmark
Forward
QuickView for Dexmedetomidine (compound)
PubChem
| Name: | Dexmedetomidine |
|---|---|
| PubChem Compound ID: | 123602 |
| Description: | A imidazole derivative that is an agonist of ADRENERGIC ALPHA-2 RECEPTORS. It is closely-related to MEDETOMIDINE, which is the racemic form of this compound. |
| Molecular formula: | C13H17ClN2 |
| Molecular weight: | 236.74 g/mol |
| Synonyms: |
Precedex; 1H-Imidazole, 4-(1-(2,3-dimethylphenyl)ethyl)-, monohydrochloride, (S)-; Dexmedetomidine hydrochloride; 4-((S)-alpha,2,3-trimethylbenzyl)imidazole monohydrochloride; 145108-58-3; Dexmedetomidine hydrochloride [USAN]
|
DrugBank
Identification
| Name: | Dexmedetomidine |
|---|---|
| Name (isomeric): | DB00633 |
| Drug Type: | small molecule |
| Description: | A imidazole derivative that is an agonist of ADRENERGIC ALPHA-2 RECEPTORS. It is closely-related to MEDETOMIDINE, which is the racemic form of this compound. |
| Synonyms: |
Medetomidine; Medetomidina [Spanish]; Medetomidinum [Latin]
|
| Brand: | PRECEDEX |
| Category: | Adrenergic alpha-Agonists, Analgesics, Non-Narcotic, Hypnotics and Sedatives, Analgesics |
| CAS number: | 113775-47-6 |
Pharmacology
| Indication: | For sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting, also used in pain relief; anxiety reduction and analgesia |
|---|---|
| Pharmacology: | Dexmedetomidine activates 2-adrenoceptors, and causes the decrease of sympathetic tone, with attenuation of the neuroendocrine and hemodynamic responses to anesthesia and surgery; it reduces anesthetic and opioid requirements; and causes sedation and analgesia. |
| Mechanism of Action: |
Dexmedetomidine is a specific and selective alpha-2 adrenoceptor agonist. By binding to the presynaptic alpha-2 adrenoceptors, it inhibits the release if norepinephrine, therefore, terminate the propagation of pain signals. Activation of the postsynaptic alpha-2 adrenoceptors inhibits the sympathetic activity decreases blood pressure and heart rate...
show more » |
| Protein binding: | 94% |
| Biotransformation: | Hepatic |
| Route of elimination: | A mass balance study demonstrated that after nine days an average of 95% of the radioactivity, following intravenous administration of radiolabeled dexmedetomidine, was recovered in the urine and 4% in the feces. Fractionation of the radioactivity excreted in urine demonstrated that products of N-glucuronidation accounted for approximately 34% of the cumulative urinary excretion. The majority of metabolites are excreted in the urine. |
| Half Life: | 2 hours |
| Clearance: | 39 L/h [Healthy volunteers receiving IV infusion (0.2-0.7 mcg/kg/hr)] |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
